NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma

Despite recent therapeutic advances, multiple myeloma (MM) remains largely incurable. Herein we report results of a phase I/II trial to evaluate the safety and activity of autologous T-cells engineered to express an affinity-enhanced T-cell receptor (TCR) recognizing a naturally processed peptide sh...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Nat Med
Huvudupphovsmän: Rapoport, Aaron P., Stadtmauer, Edward A., Binder-Scholl, Gwendolyn K., Goloubeva, Olga, Vogl, Dan T., Lacey, Simon F., Badros, Ashraf Z., Garfall, Alfred, Weiss, Brendan, Finklestein, Jeffrey, Kulikovskaya, Irina, Sinha, Sanjoy K., Kronsberg, Shari, Gupta, Minnal, Bond, Sarah, Melchiori, Luca, Brewer, Joanna E., Bennett, Alan D., Gerry, Andrew B., Pumphrey, Nicholas J., Williams, Daniel, Tayton-Martin, Helen K., Ribeiro, Lilliam, Holdich, Tom, Yanovich, Saul, Hardy, Nancy, Yared, Jean, Kerr, Naseem, Philip, Sunita, Westphal, Sandra, Siegel, Don L., Levine, Bruce L., Jakobsen, Bent K., Kalos, Michael, June, Carl H.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2015
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4529359/
https://ncbi.nlm.nih.gov/pubmed/26193344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.3910
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk